

CURRICULUM VITAE

BIOGRAPHICAL

Marcia Rochelle Silver

Birthdate: N/A
Birthplace: N/A
Citizenship: U.S.A.
Division of Nephrology and Hypertension
MetroHealth Medical Center, G-530
2500 MetroHealth Drive
Cleveland, Ohio 44109-1998
Phone: 216-778-4159

EDUCATION AND TRAINING

Undergraduate

9/68-6/70	Case Western Reserve University Cleveland, Ohio	
9/70-5/72	*The Johns Hopkins University Baltimore, Maryland	B.A., 1972 Human Biology

Graduate

9/71-5/75	*The Johns Hopkins University School of Medicine Baltimore, Maryland	M.D., 1975
-----------	--	------------

Post-Graduate

7/75-6/76	Intern in Medicine The Johns Hopkins Hospital Baltimore, Maryland	Dr. Victor McKusick Chief of Medicine
7/76-6/77	Assistant Resident in Medicine Massachusetts General Hospital Boston, Massachusetts	Dr. Alexander Leaf Chief of Medicine

*Five-Year-Program at Hopkins

7/77-6/79	Research Fellow The Robert Breck Brigham Hospital Boston, Massachusetts	Dr. K. Frank Austen Chief of Medicine (Immunology)
7/79-6/80	Clinical Fellow, Renal Division The Peter Bent Brigham Hospital Boston, Massachusetts	Dr. Barry M. Brenner Chief, Renal Division

APPOINTMENTS AND POSITIONS

7/80-3/86	University of Pittsburgh School of Medicine Pittsburgh, Pennsylvania	Assistant Professor of Medicine Renal-Electrolyte Division
3/86-5/86	University of Pittsburgh School of Medicine Pittsburgh, Pennsylvania	Associate Professor of Medicine Renal-Electrolyte Division
6/86-6/97	University of Pittsburgh School of Medicine Pittsburgh, Pennsylvania	Clinical Associate Pro- fessor of Medicine Renal-Electrolyte Division
7/80-6/81	Department of Medicine (Nephrology) Presbyterian-University Hospital Pittsburgh, Pennsylvania	Clinical Assistant Staff
7/81-5/86	Department of Medicine (Nephrology) Presbyterian-University Hospital Pittsburgh, Pennsylvania	Active Staff
7/80-5/86	Oakland Veterans Administration Medical Center Pittsburgh, Pennsylvania	Staff Physician
8/83-5/86	Department of Medicine Divisions of Internal Medicine and Nephrology Shadyside Hospital Pittsburgh, Pennsylvania	Consulting Staff
1981-1986	Presbyterian-University Hospital and Oakland Veterans Administration Medical Center Pittsburgh, Pennsylvania	Associate Director, Peritoneal Dialysis Programs
6/86-9/88	Saint Thomas Medical Center Division of Medicine Akron, Ohio	Associate Director, Department of Nephrology

6/86-6/89	Saint Thomas Medical Center Division of Medicine Akron, Ohio	Active Staff
6/89-6/97	Saint Thomas Medical Center Division of Medicine Akron, Ohio	Consultant Staff
6/86-6/89	Greater Akron Dialysis Center Akron, Ohio	Medical Staff
6/86-6/89	Cuyahoga Falls General Hospital Cuyahoga Falls, Ohio	Consulting Staff Department of Medicine
6/86-6/89	Barberton Citizens Hospital Barberton, Ohio	Courtesy Staff Department of Medicine, Section of Nephrology
6/86-6/89	Medina Community Hospital Medina, Ohio	Consulting Staff Department of Medicine
7/86-6/89	Children's Hospital Medical Center Akron, Ohio	Courtesy Staff Department of Medicine
8/86-6/89	Akron General Medical Center Akron, Ohio	Courtesy Staff Department of Medicine, Nephrology Service
8/86-6/89	Robinson Memorial Hospital Ravenna, Ohio	Consulting Staff Department of Medicine
9/86-6/89	Akron City Hospital Akron, Ohio	Courtesy Staff Departments of Internal Medicine and Nephrology
6/86-6/98	Northeastern Ohio Universities College of Medicine Rootstown, Ohio	Associate Professor of Internal Medicine
11/88-3/91	Northeastern Ohio Universities College of Medicine Rootstown, Ohio	Coordinator of Research Department of Internal Medicine
6/89-7/93	Case Western Reserve University School of Medicine Cleveland, Ohio	Assistant Clinical Professor of Medicine Division of Geriatric Medicine
6/89-12/91	Cleveland Veterans Administration Medical Center Cleveland, Ohio	Acting Medical Director Nursing Home Care Unit

9/89-12/91	Cleveland VAMC Cleveland, Ohio	Staff Physician (part time) Nephrology
1/92-7/93	Cleveland VAMC Cleveland, Ohio	Medical Director and Chief Nursing Home Care Unit
8/93-present	Department of Medicine MetroHealth Medical Center Cleveland, Ohio	Director, Hemodialysis Program, & Staff Physician Division of Nephrology and Hypertension
8/93-6/02	Case Western Reserve University	Assistant Professor of Medicine
~10/93-present	St. John's and St. Vincent's Charity Hospitals * Cleveland, Ohio	Staff Physician privileges- exclusively for outpt dialysis care.
~10/93-present	Centers for Dialysis Care Cleveland, Ohio	Medical Staff
~9/97-present	Ohio Renal Care Group** Cleveland, Ohio	Medical Staff
~9/97-present	Ohio Renal Care Group at Farnsworth** Hemodialysis Program Cleveland, Ohio	Medical Director
7/02-present	Case Western Reserve University School of Medicine Cleveland, Ohio	Associate Professor of Medicine

*our group stopped going to St. Vincent's in approximately 2002.

**Renal Care Group purchased by Fresenius Medical Care in April 2006.

CERTIFICATION AND LICENSURE

SPECIALTY CERTIFICATION:

1980	American Board of Internal Medicine
1982	American Board of Internal Medicine, Subspecialty of Nephrology
1988	American Board of Internal Medicine, CAQ in Geriatric Medicine (time limited: ten years)

MEDICAL LICENSURE:

1975	Maryland
1976	Massachusetts
1980	Pennsylvania
1986	Ohio

PROFESSIONAL SOCIETIES

1975-1980	Associate Member, American College of Physicians
1975-present	The Johns Hopkins Medical Women's Alumnae Association
1975-present	The Johns Hopkins Medical and Surgical Association
1975-1995	American Medical Women's Association
1980-present	Member, American College of Physicians (FACP, 2001)
1980-present	American Society of Nephrology
1981-present	International Society of Nephrology
1981-present	Physicians for Social Responsibility
1984-present	Women in Nephrology
1984-1991	American Federation for Clinical Research
1984-1989	Society for Health and Human Values
1986-present	Summit County Medical Association
1986-1989	American Medical Association
1986-1989	Ohio State Medical Association
1986- ~1994	International Society for Peritoneal Dialysis
1986-1989	Transplantation Society of Northeastern Ohio
1990-1994	American Geriatrics Society
1992-present	Physicians for a National Health Program

1999-2002 American Heart Association, Kidney Council

HONORS

7/01 Fellowship, American College of Physicians

7/05 Women Faculty of the School of Medicine, Case Western Reserve University, Career Development Award to fund participation in the Mid-Career Women Faculty Professional Development Seminar sponsored by the Association of American Medical Colleges (acceptance to the latter was also competitive.)

PUBLICATIONS

Refereed Articles

Lerman SJ, Silver MR, Nankervis GA, Arthralgia and rubella immunization. *Ann Intern Med* 88:131, 1978.

Silver MR, Ole-MoiYoi O, Austen KF, Spragg J. Active site radioimmunoassay for human urokinase and demonstration by radioimmunoassay of a latent form of the enzyme. *J Immunol* 124:1551-1555, 1980.

Piraino BH, Silver MR, Dominguez JH, Puschett JB. Peritoneal eosinophils during intermittent peritoneal dialysis. *Am J Nephrol* 4:152-157, 1984.

Silver MR, Sorkin MI. Insulin delivery from CAPD bags used with Peridex filters. *Peritoneal Dialysis Bulletin* 4:23-26, 1984.

Kroboth PD, Smith RB, Sorkin MI, Silver MR, Rault R, Garry M, Juhl RP. Triazolam protein binding and correlation with alpha-1-acid glycoprotein concentration. *Clin Pharmacol Ther* 36:379-383, 1984.

Rault R, Silver MR. Severe reactions during hemodialysis. *Am J Kidney Dis* 5:128-131, 1985

Silver MR, Felegie TP, Sorkin MI. Unusual bacterium, Group Ve-2, causing peritonitis in a patient on continuous ambulatory peritoneal dialysis. *J Clin Microbiol* 21:838-839, 1985.

Kroboth PD, Smith RB, Silver MR, Rault R, Sorkin MI, Puschett JB, Juhl RP. Effects of end-stage renal disease and aluminum hydroxide on triazolam pharmacokinetics. *Brit J of Clin Pharmacol* 19:839-842, 1985.

Kroboth PD, Smith RB, Rault R, Silver MR, Sorkin MI, Puschett JB, Juhl RP. Effects of end-stage renal disease and aluminum hydroxide on temazepam kinetics. *Clin Pharmacol Ther* 37:453-459, 1985.

McAuley CE, Peitzman AB, DeVries EJ, Silver MR, Steed DL, Webster MW. The syndrome of spontaneous iliac arteriovenous fistula: a distinct clinical and pathophysiologic entity. *Surgery* 99:393-377, 1986.

Amico JA, Silver MR, Finn FM, Robinson AG. High performance liquid chromatographic characterization of neurophysins in chronic renal failure. *J Lab Clin Med* 110:429-447, 1987.

Silver MR, Kroboth PD. Use of pentoxifylline in end stage renal disease: a case report. *Drug Intelligence & Clinical Pharmacy*. 2:976-978, 1987.

Sehgal AR, Snow RJ, Singer ME, Amini SB, DeOreo PB, Silver MR, and Cebul RD. Barriers to adequate delivery of hemodialysis. *Am J Kidney Dis* 31: 593-601, 1998.

Sehgal AR, Silver MR, Covinsky KE, Coffin R, and Cain JA, for the Medical Review Board of The Renal Network, Inc. Use of standardized ratios to examine variability in hemodialysis vascular access across facilities. *Am J Kidney Dis* 35:275-281, 2000.

Silver MR and Cain JA, for the Medical Review Board of The Renal Network, Inc. Managing the lifeline: preemptive access management for better outcomes for hemodialysis patients and programs. *Advances in Renal Replacement Therapy* 7: S45-S55, 2000.

Michael B, Coyne DW, Fishbane S, Folkert V, Lynne R, Nissenson AR, Agarwal R, Eschbach JW, Fadem SZ, Trout JR, Strobos J, Warnock DG. Ferrlecit Publication Committee: Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran. *Kidney Int* 61: 1830-39, 2002. (Silver on Ferrlecit Publication Committee)

Other Articles

Hamilton R, Charytan C, Kurtz S, Odgen D, Rakowski T, Schrieber M, Sorkin M, Suki W, Winchester J, Adams P, Caruana R, Burkart J, Vidt D, Piraino B, Silver M, Arty W. Reduction in peritonitis frequency by the DuPont Sterile Connection Device. *Transactions ASAIO*, 31:651, 1985.

Aronson DE, Silver MR, Christie MG, Ranjan JDR, and Anderson C. Risk factors and an intervention program for water intoxication in chronic psychiatric patients. *New Research in Mental Health (Ohio Department of Mental Health)* 12:142-151, 1996.

Silver MR: Lupus Nephritis. In *Nephrology Secrets*, DE Hricik, JR Sedor, MB Ganz (eds), Hanley & Belfus, Inc., Philadelphia, 1999. Revised for 2nd edition, copyright 2003.

Zarif L, Silver MR, and Sedor JR: Renal Vasculitis. In *Nephrology Secrets*, DE Hricik, JR Sedor, MB Ganz (eds), Hanley & Belfus, Inc., Philadelphia, 1999. For 2nd edition, 2003. Silver and Zarif, authors.

Silver MR: Uremic Pericarditis. In *Nephrology Secrets*, DE Hricik, JR Sedor, MB Ganz (eds), Hanley & Belfus, Inc., Philadelphia, 1999. Revised for 2nd edition, 2003.

Book Chapters

Silver MR. Complications of diuretic drugs. In *The Diuretic Manual*, JB Puschett, A Greenberg (eds), Elsevier, New Yourk, 1985.

Silver MR. Disorders of potassium balance. In *Disorders of Fluid and Electrolyte Balance: Diagnosis and Management*, JB Puschett (ed), Churchill Livingstone, New York, 1985.

Published Abstracts

Kroboth PD, Smith RB, Rault R, Sorkin MI, Silver MR, Puschett JB, Juhl RP. Pharmacokinetics and psychomotor effects of triazolam in dialysis patients and the effect of aluminum hydroxide on triazolam absorption. *Drug Intell Clin Pharm* 17:447A, 1983.

Silver MR, Moller MB, Black FO, Wall C III, and Puschett JB. Effects of furosemide and bumetanide on auditory and vestibular function in normal human volunteers. *Kidney Int* 23:135A, 1983.

Silver MR, Kroboth P, Sorkin MI, Durrant J, Wall C III. Vancomycin pharmacokinetics and ototoxicity in CAPD. *Kidney Int* 31: 255A, 1987.

Silver MR, Logue E, and McCord G. Rates of pericarditis associated with various treatment modalities for end stage renal disease. *J Am Soc of Nephrology* 3: 394A, 1992. (presented as poster, American Society of Nephrology annual meeting, November 1992)

Silver MR, Vo TT, Logue E, and McCord G: High normal serum potassium predicts mortality. *J Am Soc of Nephrology* 5: 373A, 1994. (presented as poster, American Society of Nephrology annual meeting, October 1994)

Sehgal AR, Silver MR, Coffin R, Cain J, and the Medical Review Board of The Renal Network (ESRD Networks 9 and 10): A standardized catheterization ratio to examine variability in vascular access use across dialysis facilities. *J Am Soc of Nephrology* 9: 226A, 1998. (presented as poster, American Society of Nephrology annual meeting, October, 1998)

Block GA, Coyne DW, Goodman WG, Silver MR, Blaisdell PW, Olson KA, Turner SA, and Lindberg JS: The calcimimetic AMG 073: A potential novel therapy for secondary hyperparathyroidism. *J Am Soc of Nephrology* 13: 572A, 2002. (presented as poster, American Society of Nephrology annual meeting, November, 2002)

Quarles LD, Zeig S, Spiegel DM, Silver MR, Vokes TJ, Torregrosa JV, Reichel H, Horl WH, Zani V, Klassen PS, Olson KA, Turner SA, and Sprague SM: Cinacalcet HCL controls secondary hyperparathyroidism (HPT) in dialysis patients regardless of disease severity. *J Am Soc of Nephrology* 14: 463A, 2003. (presented as poster, American Society of Nephrology annual meeting, November, 2003)

PROFESSIONAL ACTIVITIES

TEACHING

1. 1980 - 1989, 1993-present: Worked/work actively with house staff and students on the clinical services and specifically responsible for training fellows, residents, and students rotating in Nephrology and Medicine.
2. 1980 - 1986: Participated yearly in the Renal-Electrolyte Division's teaching of pathophysiology to medical students at the University of Pittsburgh.
3. 1986 - 1988: Participated yearly in the Nephrology Section of the Principles of Medical Science course for year IV medical students at NEOUCOM.
4. 1980 - present: Various other lectures during year, e.g., talks for residents on renal emergencies, disorders of potassium, etc.
5. 1980: Department of Medicine Grand Rounds, University of Pittsburgh: "Chronic Intermittent Peritoneal Dialysis".

6. 1982: In Continuing Medical Education program entitled "Update on Peritoneal Dialysis", sponsored by the University of Pittsburgh: Talk entitled: "Advances in the Prevention of Peritonitis in Chronic Peritoneal Dialysis".
7. 1982: In Continuing Medical Education program sponsored by the American College of Physicians: Workshop entitled "Hyper/Hyponatremia".
8. 1983: Renal Grand Rounds, Massachusetts General Hospital: "Discussion of CAPD".
9. 1985: Otolaryngology Grand Rounds, Eye and Ear Hospital of Pittsburgh: "Acute Vestibular Dysfunction in Dialysis Patients".
10. 1985: In Honors Colloquium Course at Kent State University entitled "Science and Human Values": Talk entitled: "Care of People with Chronic Illness".
11. 1985: Taught introductory medical ethics course to third year medical students at University of Pittsburgh.
12. 1986: Division of Medicine Grand Rounds, St. Thomas Medical Center: "Management of End Stage Renal Disease".
13. 1987 - 1990: Co-leader, Medical Ethics Case Conferences for junior year NEOUCOM medical students, Division of Internal Medicine, St. Thomas Medical Center, Akron, Ohio.
14. 1989 - 1990: Served as attending physician for students, house officers, and fellow in Geriatrics clinic at Cleveland VAMC.
15. 1989 - 1993: Organized and conducted "in-service" conferences for VAMC Nursing Home Care Unit staff members.
16. 1994: Medical Grand Rounds: "Management of End Stage Renal Disease", MetroHealth Medical Center, Cleveland, Ohio.
17. 1995 - present: Teach small group sessions for CWRU School of Medicine Year 1 "Homeostasis 1" course (renal pathophysiology).
18. 1997: CPC clinical discussant, MetroHealth Medical Center, A Case of Nephrotic Syndrome.
19. 1998: Led several "Medical Field Trips" for the CWRU/Robert Wood Johnson Foundation sponsored "Health Careers Enhancement Program for Minorities".
20. 1997 – 2003: Taught small groups of students in Masters Program in Bioethics of the Center for Biomedical Ethics, CWRU: Clinical Ethical Dilemmas in Patients with Kidney Disease.
21. 1999: Planned, introduced, moderated panel, and provided reference list for CME session on rationing in ESRD care and approaches to allocation of scarce resources at the Network 9 and 10 Annual Medical Conference, May, 1999, Indianapolis, Indiana.
22. 1999: "Helping your patients preserve their vascular accesses." Invited CME talk for dialysis technicians at the Network 9 and 10 Annual Medical Conference, May, 1999, Indianapolis.
23. 2000: CPC clinical discussant, MetroHealth Medical Center, A Case of Nephrotic Syndrome in a Patient with Cirrhosis.
24. 2004: Invited Lecture: "Update on Secondary Hyperparathyroidism and Calcium Sensing Receptor as a Therapeutic Target" 4/23/04 for Northern and Eastern Ohio Council on Renal Nutrition.

25. 2005: Fluid and Electrolytes Teaching Consult Service for Medical Students at MetroHealth Medicine Center, aka "Salt and Water Club".

RESEARCH

Grants received

1983-4: Insulin Delivery from CAPD bags used with Peridex Filters, and Studies of Peridex Filters for Prevention of Peritonitis in CAPD, Millipore Corp. (P.I.).

1985: Vancomycin Pharmacokinetics and Ototoxicity in CAPD, Eli Lilly and Co. (P.I.).

1985: (and renewed in 1986), Prevention of Auditory and Vestibular Impairment in Patients with Renal Disease, Deafness Research Foundation. (P.I.).

1990: Water Intoxication Research Project: I. An innovative approach to management of compulsive water drinkers in the psychiatric hospital setting; II. Case control study of compulsive water drinking in a state psychiatric hospital, Ohio Department of Mental Health, Office of Program Evaluation Research. (co-investigator) (continued through 1994).

1991: Rates of Pericarditis Associated with Various Treatment Modalities for End Stage Renal Disease. An analysis of United States Renal Data System (USRDS) data through the Investigator-Initiated Research Program. Funded by the Kidney Foundation of Summit County (Ohio). (P.I.).

1993: NEOUCOM Summer Fellowship Program, (as preceptor for a medical student): Hyperkalemia in the Elderly: Incidence, Risk Factors, and Consequences. (P.I.) (covered student stipend).

1993: Factors Affecting Survival Differences between Older and Younger Dialysis Patients. Kidney Foundation of Summit County (Ohio) (P.I.), (\$5,308).

1994: Relationships Between Comorbidity, Dialysis Pericarditis, and Dialysis Modality. Leonard C. Rosenberg Renal Research Foundation (Cleveland), (P.I.) (\$17,975).

MULTICENTER CLINICAL TRIALS

1998 - 1999: A randomized, double-blind, non-inferiority study of IV Novel Erythropoiesis Stimulating Protein (NESP) compared to IV Recombinant Human Erythropoietin (r-HuEPO) for treatment of anemia in patients with End-Stage Renal Disease (ESRD) receiving hemodialysis. (NESP 980117). Sponsored by Amgen, Inc.

1998 - 1999: An open label, randomized study of Novel Erythropoiesis Stimulating Protein (NESP) and Recombinant Human Erythropoietin (r-HuEPO) for the treatment of anemia in patients with End-Stage Renal Disease (ESRD) receiving hemodialysis. (NESP 980211). Sponsored by Amgen, Inc.

1999 - 2000: A randomized study comparing the efficiency of once weekly vs. three times weekly administration of intravenous Novel Erythropoiesis Stimulating Protein to subjects with End-Stage Renal Disease receiving hemodialysis. (NESP 990773). Sponsored by Amgen, Inc.

1999 - 2000: A phase IV clinical protocol: Crossover, randomized, blinded, prospective, multicenter clinical evaluation of the rate of adverse events to Ferrlecit ® in hemodialysis patients as compared to placebo and historical controls (FER 9803). Sponsored by R & D Labs, Inc.

2001 - 2002: A Phase II clinical protocol: A randomized, double-blind placebo-controlled study to assess the efficacy and safety of an oral calcimimetic agent (AMG 073) in secondary hyperparathyroidism of chronic renal failure. Protocol Number 20000237. Sponsored by Amgen, Inc.

2001 - 2003: A Phase II clinical protocol: A multicenter, open-label extension study to assess the long term safety and efficacy of an oral calcimimetic agent (AMG 073) in secondary hyperparathyroidism of end-stage renal disease (ESRD). Protocol Number 20000130. Sponsored by Amgen, Inc.

2001: A Phase II clinical protocol: A pilot study to assess the impact of anemia correction with Novel Erythropoiesis Stimulating Protein (NESP) on sleep disorders in subjects with Chronic Renal Insufficiency (CRI). Sponsored by Amgen, Inc. (cancelled by company because drug approved by FDA.)

2001 - 2003: A Phase III clinical protocol: A Phase III study to assess the efficacy and safety of an oral calcimimetic agent (AMG 073) in secondary hyperparathyroidism of End Stage Renal Disease treated with hemodialysis. Protocol Number 20000172. Sponsored by Amgen, Inc.

2002 - present: A study of Darbepoetin alfa administered once every four weeks in Chronic Renal Insufficiency (CRI) subjects with anemia. Protocol Number 20010212. Sponsored by Amgen, Inc.

2002 - 2003: A Placebo-controlled, double-blind, extension study to assess the long-term safety of an oral calcimimetic agent (AMG 073) in secondary hyperparathyroidism of end-stage renal disease. Protocol Number 20010240. Sponsored by Amgen, Inc.

2002 - present: A Randomized, Double Blind Study Comparing Aranesp (Darbepoetin alfa) and Recombinant Human Erythropoietin (rHuEPO) in the Treatment of Anemia in African American Subjects with Chronic Renal Failure (CRF) receiving Hemodialysis. Protocol Number 20010125. Sponsored by Amgen, Inc.

2004 - present: A Multicenter, Single Arm Study Evaluating Once Monthly Darbepoetin Alfa Dosing in Subjects with Chronic Kidney Disease Not Receiving Dialysis. Protocol Number 20030153. Sponsored by Amgen, Inc.

2004 – present: A Multicenter, Single Arm Study Evaluating De Novo Once Every Two Week Darbepoetin Alfa Dosing in Subjects With Chronic Kidney Disease Not Receiving Dialysis. Protocol Number 20030237. Sponsored by Amgen, Inc.

2004 – present: A randomized, controlled, open-label, multi-center, parallel-group study to demonstrate the efficacy and safety of RO 0503821 when administered with pre-filled syringes for the maintenance treatment of anemia in patients with Chronic Kidney Disease who are on dialysis. Protocol Number BA17284. Sponsored by Hoffmann-LaRoche, Inc.

2004 – present: An Open-Label, Single-Arm Study to Assess the Safety of Darbepoetin alfa Manufactured by a Serum Free Bioreactor Technology in Subjects with Chronic Kidney Disease. Protocol Number 20040180. Sponsored by Amgen, Inc.

2005 – present: An Open-Label, Single-Arm Study to Assess the Safety of Epoetin Alfa Manufactured by a Deep Tank Technology in Subjects with Chronic Kidney Disease Receiving Dialysis. Protocol Number 20040268. Sponsored by Amgen, Inc.

2005 – present: An Open-Label, Multi-Center Study to Document the Efficacy, Safety and Tolerability of Long-Term Administration of R00503821 In Patients with Chronic Renal Anemia. Protocol Number

BH18387. Sponsored by Hoffmann-LaRoche, Inc.

2005 – present: Trial to Reduce Cardiovascular Events with Aranesp® Therapy Study. Protocol Number 20010184. Sponsored by Amgen, Inc.

OTHER ACTIVITIES (Service)

1983 - 1985: Served on Internship Selection Committee, Department of Medicine, Presbyterian-University Hospital Program, University of Pittsburgh.

1984 - 1993: Reviewer for Peritoneal Dialysis International (previously Peritoneal Dialysis Bulletin).

1985: Project consultant, educational videotape entitled "A Closer Look at The Institutional Ethics Committee", produced by Northeastern Ohio Universities College of Medicine Human Values in Medicine program.

1986 - 1987: Program Chairperson, Transplantation Society of Northeastern Ohio.

1987 - 1989: Chairperson, Research Committee (IRB) of St. Thomas Hospital Medical Center, Akron.

1988 - 1991: NEOUCOM representative to American Federation for Clinical Research.

1990 - 1996: Research Development Chair, Kidney Foundation of Summit County.

1992: Served on Cleveland VAMC Task Force on Advance Directives.

1992 - 1993: Member, Bioethics Committee, Cleveland VAMC.

1994 - 2002: Member, Medical Ethics Subcommittee, MetroHealth Medical Center.

1995 - 1999: Executive Council member, Council on Dialysis, National Kidney Foundation.

1995: Appointed member, MetroHealth Medical Center Ventilator Care Team (committee to examine ventilator care program at MetroHealth and consider alternatives to improve care).

1/1/96 - 12/31/98: Elected member, Medical Review Board, Tri-State Renal Network (Network 9, based in Indianapolis).

1/1/99 - 12/31/01: Elected member, Medical Review Board, representing Network 9, The Renal Network, Inc. (Networks 9 and 10, based in Indianapolis) (Data Analysis Subcommittee; Program Planning Committee for the Annual Conference).

1/1/02 - 12/31/04: Elected member, Medical Review Board, representing Network 9, The Renal Network, Inc. (Networks 9 and 10, based in Indianapolis) (Data Analysis Subcommittee; Program Planning Committee for the Annual Conference).

1998 - present: Appointed member, Quality Council of the Ohio Renal Care Group.

1998 - present: Appointed member, Clinical Management Team for Medical Specialties Clinics at MHMC.

2002 - 2003: Appointed member, General Clinical Research Center Protocol Review Committee, CWRU GCRC at MHMC.

- 2002 -2003: Participant: The MetroHealth System, System-Wide Focus on Geriatrics Group,
Subcommittee: System-Wide Clinical Project.
- 2003 : appointed member: National Kidney Disease Education Project (NKDEP) Cleveland
Coalition.
- 2003: Fiscal Innovation Committee of the Department of Medicine at MHMC.
- 2004 - present: appointed member, MHMC ad hoc committee on Clinical Trials.
- 1/1/06 - 12/31/09: Elected member, Medical Review Board, representing Network 9, The Renal Network,
Inc. (Networks 9 and 10, based in Indianapolis) (Data, Quality Improvement and
Patient Safety Subcommittee; Program Planning Committee for the Annual Conference).

(revised: 5/2006)